Keywords: Inflammatory Bowel Disease, Pediatric patient, Cox 2; CD45+ and CD45- cells; TNF; Cytokine expression

Abbreviations: IBD: Inflammatory Bowel Disease; SCSR: Somatic Cell Sampling and Recovery; IgA: Immunoglobulin A; IgG: Immunoglobulin G; COX-2: Cyclooxygenase 2; TNF: Tumor Necrosis Factor; IL: Interleukin

Introduction

Inflammatory Bowel Disease (IBD) is a major chronic illness among children, adolescents and young adults (recent reviews) [1-4]. In ulcerative colitis and Crohn’s disease, the two major forms of IBD, a persistent inflammatory reaction is an integral component of the clinical manifestations of this disease. Ulcerative colitis typically presents with blood in the stools and diarrhea. The onset may be insidious and only if symptoms last for over 2 weeks is a diagnosis of IBD rather than an infectious etiology considered. Crohn’s disease may present with GI symptoms including abdominal pain and bloody diarrhea, however systemic manifestations are more common than with ulcerative colitis. These include fever, malaise, easy fatigability, growth failure, anemia, skin rashes, and arthritis [3,4]. Diagnosis of ulcerative colitis is made by endoscopy and colonic biopsy; barium enema has no place in the diagnosis of UC. A diagnosis of Crohn’s disease is made from the history, physical, laboratory findings (Hb, Hct, WBC, ESR, CRP), endoscopy and radiologic examination [5]. These diagnostic studies, although essential for establishing the diagnosis, are highly invasive, expensive, and inconvenient for the patient. This is particularly true because the disease is chronic and these tests may need to be repeated. Nevertheless, the differential diagnosis between the two IBD forms is complicated by the overlapping clinical presentations, similar outcomes in non-invasive tests, and by the histological evaluation of intestinal biopsies that sometimes does not show typical features of either condition. Once a diagnosis is made the clinical course of the disease during treatment is assessed largely by following the subjective reports of the patient and frequent repeat endoscopies. The diagnosis and continued clinical management of IBD is expensive and time consuming (in terms of clinician time per patient). Previous studies have shown that colonic cells can be recovered in a viable state from stool samples and examined for the presence of cells carrying specific biomarkers of neoplastic transformation [6-16]. Recent studies have indicated that alterations in cytokine synthesis may play a role in inflammatory bowel disease (IBD) pathogenesis. Cytokines studied in IBD patients included TNF-alpha, TGF-beta, IL-1, IL-10, IL-6, IL-12, IL-18, IL-23, IL-27, and IFN-gamma [17-20]. Following confirmatory endoscopy, this relatively inexpensive laboratory procedure could be used as an effective diagnostic tool.

Abstract

Objectives: The diagnosis (endoscopy, and biopsy) and continued clinical management of Inflammatory Bowel Disease (IBD), remain highly invasive, expensive, and inconvenient for the pediatric patient. The objective of this study was to see if colonicocytes obtained from stools of subjects with IBD and normal controls would demonstrate higher levels of inflammatory markers (Cox 2 in CD45+ and CD45- cells) and if the inflammatory process and treatment effects would be reflected in an altered cytokine expression in the subjects compared to controls.

Setting: Outpatient hospital based pediatric gastroenterology clinic.

Methods and Main outcome measures: Stool samples (~ 1 gm), were obtained from 18 children between the ages of 4 and 18 diagnosed with IBD, and from a normal first degree relative. Colonicocytes were isolated using the Somatic Cell Sampling Recovery (SCSR) system and assessed for the expression of COX-2, CD45, IgA, IgG, IL6, IL18, TGF B, TNF, and IL16B using flow cytometry. In addition, levels of COX-2 and cytokeratin 19 transcripts were measured by microwell plate hybridization assay.

Results: Expression of COX-2 and co-expression of IgA and IgG were significantly higher in the IBD cases compared to the controls. In ulcerative colitis, the expression of COX-2 and co-expression of COX-2 and CD45 were greater than that in patients with Crohn’s disease. In contrast, cells expressing IgA and IgG were higher in Crohn’s. Subjects on immunosuppressants and/or anti-inflammatory medications, expressed significantly lower levels of COX-2 and IL-18 compared to those who were not on treatment.

Conclusions: This study indicates that the use of disease markers on exfoliated colonic cells can be used for non-invasive assessment of disease status, for follow-up of response to treatment and for forecasting flare-up of disease before its symptomatic manifestations.
assist in those cases in which the differential diagnosis between Crohn’s disease and ulcerative colitis is difficult and could be used to monitor the patient’s clinical progress during treatment, repeatedly, without undergoing the usual invasive procedures. The purpose of this study was to see if colonocytes obtained from stool of subjects with IBD would demonstrate higher levels of inflammatory markers compared to normal controls and if inflammatory process and treatment effects would be reflected in an altered cytokine expression in the subjects compared to controls. This study was designed as an initial proof of concept for this new approach to the pathophysiology of IBD at the cellular level, noninvasively.

**Materials and Methods**

**Patients and Procedures**

Children between 4 and 18 years, with a diagnosis of IBD, followed in the Pediatric Gastroenterology Clinic of the University of Maryland Hospital in Baltimore, were eligible for enrollment. The Institutional Review Board approved the study. A nurse patient coordinator reviewed the study protocol with the patient and/or parents to ascertain eligibility and obtained informed consent for participation. Non-symptomatic first degree relatives (siblings or parents) of subjects who were willing to cooperate were enrolled as control subjects. Twenty four families consented to participate in the study. Study participants, were asked to provide two 0.5 gm stool samples collected on consecutive days within five days prior to clinically indicated colonoscopy. A clinical research nurse administered a questionnaire to obtain patient’s subjective perception of health status.

**Sample collection**

The patients were provided with a stool collection kit consisting of two screw-capped collection vials containing 15 ml of a nontoxic transport medium. Approximately, 0.5 gm of stool was collected using the plastic ladle attached to the screw cap and placed in the liquid medium. The tube was capped and the sample sent to the research laboratory via courier without refrigeration. When the samples arrived in the laboratory, they were logged in and processed for the isolation of exfoliated colonic cells [13].

**Immunological Assays on Exfoliated Cells**

**COX-2, CD45, IgA, and IgG expression on exfoliated colonocytes** Cell surface markers were assessed using flow cytometry. For each of the patients and controls 2 stool samples were collected on two separate days, a week before the patient’s scheduled colonoscopy. Colonial cells from the interface and pellet were isolated for analysis.

**Quantification of mRNA by Microtiter Plate Hybridization Assay**

Levels of COX-2 and cytokinin 19 transcripts in colonocyte samples were measured using microowell plate hybridization assay. COX-2 and cytokerin 19 synthetic oligonucleotides (sense) aminated at the 5’ end via a C12 linker were used as capture probes, covalently attached to a 96 microwell plate (Costar) coated with reactive N-hydroxysuccinimide ester groups (NOS) (DNA-BIND, Corning, New York). Following coupling and blocking of residual NOS groups, N-hydroxysuccinimide ester groups (NOS) (DNA-BIND, Corning, New York). Following coupling and blocking of residual NOS groups, were used as a positive control in all the gene expression assays.

**Oligonucleotide probes and primers**

All synthetic oligonucleotides used for the study were designed using Primer3 software (MIT, Boston, MA) from published sequences (GenBank Accession# M90100 for Cox-2 & GenBank Accession# BC007628 for Cytokeratin 19). The oligonucleotides were synthesized by Sigma Genosys (The Woodlands, TX). Sequences are as follows:

**Capture probes:**
- **Cox-2:** 5’-biotin-TGG CTA CAG CCA TAC AGC AGG AGG AAG GGC AGC CTT-3’ (nt 457-480).
- **Cytokeratin19:** 5’H2N-AGC TGG CTA CAG CCA TAC AGC AGG AAG GGC ACT G-3’ (nt 997-1018).

**Biotinylated control oligonucleotides:**
- **Cox-2:** 5’-biotin-GGT TAG AGA AGG CTT CCC AGC TTT TGT AGC CAT AGT CAG C-3’ (nt 488-449).
- **Cytokeratin19:** 5’-biotin-GGT TGC CTT GAG AGA CAC ACT G-3’

**PCR primers:**
- **Cox-2 (F):** 5’-GGT AGG CAG GAA AAG AAG GAG GGC-3’
- **Cox-2 (R):** 5’-GTG AGT TAC ATC ATC AGC CAG AAC AGG AGG AGG GC-3’
- **Cytokeratin19 (F):** 5’-ATG CTT CTG CTA AAC AGC AAG AAG AAG GGC-3’
- **Cytokeratin19 (R):** 5’-biotin-CAT GAG CCG CTC GTG TGT GGA AAC AAA-3’

**RNA Extraction**

Total RNA was isolated from colonocytes and LS180 cells with the Pico Pure™ RNA isolation kit (Arcturus, Mountain View, CA) according to the manufacturer’s instructions. Genomic DNA was degraded using on-column digestion with 25 U of RNase-free DNAsel I (Ambion, Austin, TX) for 30 min and the RNA eluted with 30 μl of nuclease-free water.

**RT-PCR**

First strand cDNA was prepared from 200 ng of total RNA extracts using a commercial kit (Thermoscript RT-PCR system for First-Strand cDNA synthesis; Invitrogen, Carlsbad, CA). Negative controls consisted of cDNA templates with no reverse transcriptase to test for the absence of genomic DNA.

**Agarose gel electrophoresis**

RT-PCR products were analyzed by electrophoresis on 2% agarose gels, stained with SYBR green I (Invitrogen, Carlsbad, CA) and visualized under UV illumination.

**Quantification of mRNA by microtiter plate hybridization assay**

Levels of Cox-2 and cytokinin 19 transcripts in colonocyte samples were measured using microowell plate hybridization assay.

**Measurement of Intracellular Cytokines**

Flow Cytometry assays for surface antigens of COX-2, IgA, and IgG were performed using a direct staining technique as described by Nair et al. [13] LS180 (colon carcinoma cell line, ATCC # CL-187) was used as a positive control in all the gene expression assays.
Immobilization of capture probes

Immobilization of capture probes was performed according to the manufacturer’s instructions. Cox-2 and cytokeratin 19 capture probes (25 pmoles) in 100 µl of coating buffer (50 mM sodium phosphate, pH 8.5, 1 mM EDTA) was added to each well of DNA-Bind plate.

Statistical analyses

Statistical analyses were performed using the Statistical Package for Social sciences 11.5 (SPSS Inc., Chicago, Il, 2002). Inflammatory surface markers and intracellular cytokine expression in patients and controls were compared. Statistical significance was determined using *t* tests and Chi-Square Tests. We considered a *P* value of ≤ 0.05 significant. As recommended by Lipsey for some of the variables we set an alpha size [21]. Although this approach increases the possibility of a Type I error (erroneously reporting a difference), it decreases the likelihood of a Type II error (reporting no difference when a difference exists) [21]. A multivariate analysis of variance was conducted to estimate the effect of severity of clinical symptoms, colonoscopy findings, pathological findings/diagnosis, treatment and demographic characteristics on inflammatory markers/cytokines.

**Results**

**Clinical Characteristics of the Patients**

Twenty four families agreed to participate, of which 22 families completed the study as designed. Adequate stools were received from 18 subjects whose clinical symptoms are listed on (Table 1). There was

---

**Table 1: Characteristics of Study Population.**

<table>
<thead>
<tr>
<th>No</th>
<th>Colonoscopy Diagnosis</th>
<th>No. of site in colonoscopy</th>
<th>Path severity</th>
<th>Path diagnosis</th>
<th>No. of sites on path.</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Inflammatory activity recto-sigmoid &amp; cecal area</td>
<td>4</td>
<td>moderate</td>
<td>Crohn's</td>
<td>6</td>
</tr>
<tr>
<td>2</td>
<td>Ulcerative pancolitis</td>
<td>6</td>
<td>moderate</td>
<td>Ulcerative colitis</td>
<td>3</td>
</tr>
<tr>
<td>3</td>
<td>Left sided ulcerative colitis</td>
<td>2</td>
<td>moderate</td>
<td>Ulcerative Colitis</td>
<td>5</td>
</tr>
<tr>
<td>4</td>
<td>4 yr old with abdominal pain</td>
<td>1</td>
<td>normal</td>
<td>Lymphoid hyperplasia, eosinophilis</td>
<td>2</td>
</tr>
<tr>
<td>5</td>
<td>congested mucosa entire colon</td>
<td>2</td>
<td>moderate</td>
<td>Crohn's</td>
<td>3</td>
</tr>
<tr>
<td>6</td>
<td>Moderate protoclocculitis, erythma mucosa, congested mucosa spheric flex</td>
<td>1</td>
<td>severe</td>
<td>Ulcerative Colitis</td>
<td>2</td>
</tr>
<tr>
<td>7</td>
<td>Diffuse congested mucosa &amp; petechiae entire colon</td>
<td>7</td>
<td>moderate</td>
<td>Ulcerative Colitis</td>
<td>6</td>
</tr>
<tr>
<td>8</td>
<td>Congested mucosa in sigmoid</td>
<td>1</td>
<td>moderate</td>
<td>Ulcerative Colitis</td>
<td>5</td>
</tr>
<tr>
<td>9</td>
<td>Stricture cecum, granularity ileum suspicious of Crohn's</td>
<td>0</td>
<td>mild inflammation</td>
<td>Ulcerative Colitis</td>
<td>1</td>
</tr>
<tr>
<td>10</td>
<td>Normal</td>
<td>0</td>
<td>mild inflammation</td>
<td>normal</td>
<td>1</td>
</tr>
<tr>
<td>11</td>
<td>Pseudopolyphoid sigmoid &amp; descending colon</td>
<td>3</td>
<td>moderate</td>
<td>Crohn's</td>
<td>12</td>
</tr>
<tr>
<td>12</td>
<td>Ileo-colonoc Crohn's, external &amp; internal hemorrhoids</td>
<td>5</td>
<td>mild inflammation</td>
<td>Crohn's</td>
<td>6</td>
</tr>
<tr>
<td>13</td>
<td>A few aphthous ulcers rectum sigmoid, transverse colon</td>
<td>5</td>
<td>moderate</td>
<td>Crohn's</td>
<td>6</td>
</tr>
<tr>
<td>14</td>
<td>Mucosal ulceration sig, desc, left trans, congested muc: rt trans</td>
<td>7</td>
<td>severe</td>
<td>Crohn's</td>
<td>6</td>
</tr>
<tr>
<td>15</td>
<td>Ileoocolonic Crohn's</td>
<td>1</td>
<td>moderate</td>
<td>Ulcerative Colitis</td>
<td>2</td>
</tr>
<tr>
<td>16</td>
<td>Mucosal ulceration, colonic Crohn's disease</td>
<td>7</td>
<td>severe</td>
<td>Crohn's</td>
<td>6</td>
</tr>
<tr>
<td>17</td>
<td>Diffuse area of erythematous mucosa in cecum,</td>
<td>2</td>
<td>severe</td>
<td>Crohn's</td>
<td>7</td>
</tr>
<tr>
<td>18</td>
<td>Rect, sig normal, nonbleeding ulceration desc, trans,cecum colon, granularity of mucosa</td>
<td>5</td>
<td>moderate</td>
<td>Crohn's</td>
<td>6</td>
</tr>
</tbody>
</table>

---

**Table 2: Assessment of Disease Severity.**

<table>
<thead>
<tr>
<th>No</th>
<th>Colonoscopy Diagnosis</th>
<th>Path severity</th>
<th>Path diagnosis</th>
<th>No. of sites on path.</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Inflammatory activity recto-sigmoid &amp; cecal area</td>
<td>moderate</td>
<td>Crohn's</td>
<td>6</td>
</tr>
<tr>
<td>2</td>
<td>Ulcerative pancolitis</td>
<td>moderate</td>
<td>Ulcerative colitis</td>
<td>3</td>
</tr>
<tr>
<td>3</td>
<td>Left sided ulcerative colitis</td>
<td>moderate</td>
<td>Ulcerative Colitis</td>
<td>5</td>
</tr>
<tr>
<td>4</td>
<td>4 yr old with abdominal pain</td>
<td>normal</td>
<td>Lymphoid hyperplasia, eosinophilis</td>
<td>2</td>
</tr>
<tr>
<td>5</td>
<td>congested mucosa entire colon</td>
<td>moderate</td>
<td>Crohn's</td>
<td>3</td>
</tr>
<tr>
<td>6</td>
<td>Moderate protoclocculitis, erythma mucosa, congested mucosa spheric flex</td>
<td>severe</td>
<td>Ulcerative Colitis</td>
<td>2</td>
</tr>
<tr>
<td>7</td>
<td>Diffuse congested mucosa &amp; petechiae entire colon</td>
<td>moderate</td>
<td>Ulcerative Colitis</td>
<td>6</td>
</tr>
<tr>
<td>8</td>
<td>Congested mucosa in sigmoid</td>
<td>moderate</td>
<td>Ulcerative Colitis</td>
<td>5</td>
</tr>
<tr>
<td>9</td>
<td>Stricture cecum, granularity ileum suspicious of Crohn's</td>
<td>mild inflammation</td>
<td>Ulcerative Colitis</td>
<td>1</td>
</tr>
<tr>
<td>10</td>
<td>Normal</td>
<td>mild inflammation</td>
<td>normal</td>
<td>1</td>
</tr>
<tr>
<td>11</td>
<td>Pseudopolyphoid sigmoid &amp; descending colon</td>
<td>moderate</td>
<td>Crohn's</td>
<td>12</td>
</tr>
<tr>
<td>12</td>
<td>Ileo-colonoc Crohn's, external &amp; internal hemorrhoids</td>
<td>mild inflammation</td>
<td>Crohn's</td>
<td>6</td>
</tr>
<tr>
<td>13</td>
<td>A few aphthous ulcers rectum sigmoid, transverse colon</td>
<td>moderate</td>
<td>Crohn's</td>
<td>6</td>
</tr>
<tr>
<td>14</td>
<td>Mucosal ulceration sig, desc, left trans, congested muc: rt trans</td>
<td>severe</td>
<td>Crohn's</td>
<td>6</td>
</tr>
<tr>
<td>15</td>
<td>Ileoocolonic Crohn's</td>
<td>moderate</td>
<td>Ulcerative Colitis</td>
<td>2</td>
</tr>
<tr>
<td>16</td>
<td>Mucosal ulceration, colonic Crohn's disease</td>
<td>severe</td>
<td>Crohn's</td>
<td>6</td>
</tr>
<tr>
<td>17</td>
<td>Diffuse area of erythematous mucosa in cecum,</td>
<td>severe</td>
<td>Crohn's</td>
<td>7</td>
</tr>
<tr>
<td>18</td>
<td>Rect, sig normal, nonbleeding ulceration desc, trans,cecum colon, granularity of mucosa</td>
<td>moderate</td>
<td>Crohn's</td>
<td>6</td>
</tr>
</tbody>
</table>
an equal distribution of males to females (m=9, f=9), 9.1% reported a family history of IBD, 77.7% were Caucasian and 22.3% African American. Seven subjects reported mild abdominal pain (38.9%), 5 moderate pain, (27.8%) and 6 none (33.3%). Total signs on the Harvey Bradshaw index ranged from 0 to 7 [22].

Assessment of severity by colonoscopy and histology are listed on (Table 2) Seven (38.9%) had evidence of ulcerative colitis, 11 (61.1%) had diagnosis of Crohn’s by colonoscopy or pathology. Histopathology showed evidence of severe inflammation in 4 (22.2%), moderate inflammation in 10 (55.5%), mild or none in 4 (22.2%). Eight (44.4%) of the subjects were on immunosuppressants and/or antimetabolite treatment.

Expression of COX-2 in exfoliated cells from patients compared with controls

Figure 1 shows that the expression of COX-2 was significantly higher in the IBD cases compared to the controls (p value 0.007). Co-expression of COX-2 +CD45 and IgA + IgG as determined by two-color flow cytometry was elevated in IBD but did not reach statistical significance (p value 0.06 and 0.08 respectively). Individually, CD 45, IgA, and IgG were similar in patients compared to controls. In this analyses all patients, regardless of their disease status were compared to their first degree relatives (control).

Figure 2 presents results of COX-2 mRNA expression (pellet and interface). In general COX-2 expression in IBD patients was consistently higher than in the corresponding normal subjects but did not reach statistical significance (p value 0.07). However the values reached statistical significance when adjusted for the expression of housekeeping protein cytokeratin 19 (p value 0.04)

Expression of intracellular cytokines in patients compared with controls

Intracellular cytokines IL6, IL18, TGF β, TNF and COX-2 are presented in Figure 3. COX-2 was significantly higher in subjects compared to controls (p value 0.04) Cytokine levels were lower in IBD compared to normal subjects, TGF β was also lower in IBD patients (p value 0.01). IL6 was detected in only one of the IBD patients, but was present in 5 of the normal subjects.

Response of inflammatory markers to treatment with immunosuppressants

Within the group of IBD patients, those who were on immunosuppressants and/or anti-inflammatory medications, expressed significantly lower levels of COX-2 and IL-18 compared to those who were not on treatment (Figure 4). In contrast, in this treated group the number of cells expressing IgG by itself was enhanced (Figure 4) compared to the untreated group.

Characteristics distinguishing Crohn’s from ulcerative colitis

Analysis of cells from patients with Crohn’s or ulcerative colitis and their normal first degree relatives indicated that children with ulcerative colitis had significantly higher levels of COX-2 and coexpression of COX-2 and CD45 compared to the other two groups (Figure 5). Patients with Crohn’s had significantly higher numbers of IgA and IgG positive cells when compared to patients with ulcerative colitis and normal first degree relatives.

Discussion

We applied this noninvasive approach to screen patients suspected of suffering from IBD by demonstrating the presence of inflammatory cells in stools. Following confirmatory endoscopy, this relatively inexpensive laboratory procedure could assist in those cases in which the differential diagnosis between Crohn’s disease and ulcerative colitis is difficult and could be used to monitor the patient’s clinical progress during treatment, repeatedly, without undergoing the usual invasive procedures. Enumeration of inflammatory cells by two-color immunofluorescent flow cytometry provides a means of monitoring inflammatory activity to follow epithelial restitution of the colonic mucosa during periods of remission. The feasibility of this approach has been demonstrated in an earlier report [23].

Using a noninvasive approach for isolating colonic epithelial cells from stool samples, we were able to study the expression of COX-2, IgA, IgG, cytokines and CD45 as determined by two-color flow cytometry were significantly higher in the IBD patients compared to controls. CD45 alone as a measure of inflammatory cells showed no difference.
In our study, cells expressing IgA and IgG were more numerous in Crohn’s disease compared to those from ulcerative colitis. Our hypothesis is that this is indicative of a hyperimmune response at the epithelial level of the mucosa, characteristic of this condition.

Analyses of biomarkers on exfoliated colonic cells can be used for the assessment of disease status, for follow-up of response to treatment and for forecasting flare-up of disease before symptomatic manifestations. Furthermore, in earlier studies we have established the fact that cells isolated by the SCSR technique is anatomically representative of the entire colonic mucosa starting at the ileo-caecal junction [8,15,26]. This is based on the fact that cells expressing the blood group antigen, detectable in our cell isolates, originate only from the proximal segments (caecum and proximate colon) of the colon.

The distinct advantage of this procedure is that it can be performed repeatedly without any discomfort to the patient. This study has shown the feasibility of monitoring patients with IBD in a noninvasive manner.

**Funding**

This project has been funded by an SBIR grant R44-DK56567 from the US National Institutes of Health, National Institutes of Diabetes, Digestive and Kidney Diseases.

**Competing Interests**

PPN and PN are Principals in NonInvasive Technologies LLC

**Ethics approval**

This study was conducted with the approval of the Institutional Review Board of the University of Maryland School of Medicine and Hospital.

**Significance of this study**

**What is already known about this subject?**

- Inflammatory Bowel Disease is associated with an inflammatory process of the bowel mucosa.
- Endoscopy followed by colonic biopsy to detect the presence of an inflammatory process by means of microanatomic pathology is the established standard of diagnosis and follow-up during treatment.
These procedures, though essential for establishing a diagnosis, are invasive, and particularly traumatic for children when the disease is chronic and may need to be repeated.

What are the new findings?

Significant numbers (in the millions) of viable colonic cells can be recovered from a small sample of stool (1.0 gm) from these patients and quantitatively assessed for the presence of inflammatory cells while delineating them by lineage (epithelial versus lymphoid).

This procedure (Somatic Cell Sampling and Recovery, SCSR™) allows for a true sampling of all exfoliated cells, anatomically representative of the entire colonic mucosa, from the ileo-caecal junction to the rectum.

Patients with inflammatory bowel disease are distinguishable from their unaffected first degree relatives by the presence of cells of both lymphoid (CD 45+) and non-lymphoid lineage (CD 45-) expressing markers of inflammation (COX-2 and cytokines).

The quantitative burden of inflammatory cells in a stool sample is consistent with disease severity as assessed by endoscopy and microanatomical pathology.

Response to therapy with immunomodulators was reflected in a concomitant decrease in the percentage of inflammatory cells.

How might it impact on clinical practice in the foreseeable future?

The technology allows for a non-invasive approach to the repeated monitoring of disease severity as well as response to treatment of pediatric IBD patients.

The feasibility of obtaining viable exfoliated colonic cells, non-invasively should encourage further investigations into the characterization of these cells for their disease propensities.

References


Submit your next manuscript and get advantages of OMICS Group submissions

Unique features:

• User-friendly/friendly website-translation of your paper to 50 world’s leading languages
• Audio Version of published paper
• Digital articles to share and explore

Special features:

• 200 Open Access Journals
• 15,000 editorial team
• 21 days rapid review process
• Quality and quick editorial, review and publication processing
• Indexing at PubMed (partial), Scopus, DOAJ, BSBSC, Index Copernicus and Google Scholar etc
• Sharing Options, Social Networking Enabled
• Authors, Reviewers and Editors rewarded with online Scientific Credits
• Better discount for your subsequent articles

Submit your manuscript at: http://omicsinfo.com/editorialtracking/